VERQUVO (Bayer Australia Ltd)
Product name
VERQUVO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
199 (255 working days)
Active ingredients
vericiguat
Registration type
NCE/NBE
Indication
VERQUVO (film-coated tablet) is indicated in addition to standard of care therapy for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction less than 45% who are stabilised after a recent heart failure decompensation event requiring admission and/or IV diuretic therapy (see Section 5.1 Pharmacodynamic properties - Clinical trials).